CLINICAL TRIALS PROFILE FOR VIRILON

All Clinical Trials for VIRILON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04731376 ↗	Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone	Recruiting	Emory University	Phase 1	2021-01-25	This phase I trial investigates the safety of testosterone replacement therapy around the time of major urologic surgery (perioperative) in order to improve quality of life and post-operative outcomes such as decreased length of hospital stay, complications, and mortality in patients with low testosterone levels. Studies have demonstrated that patients undergoing testosterone replacement therapy have increased lean body mass, decreased fat mass and have improved physical function. Testosterone replacement therapy can also stimulate bone formation and may decrease the risk of fracture. Information from this trial may be used to support the incorporation of testosterone level testing and testosterone replacement into the perioperative treatment decision-making process.
NCT06039371 ↗	Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study	Recruiting	National Cancer Institute (NCI)	Phase 2	2024-06-06	This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer). In patients that have developed progressive cancer in spite of standard hormonal treatment, administering supraphysiological testosterone may result in regression of tumors by causing deoxyribonucleic acid (DNA) damage in tumor cells that have adapted to low testosterone conditions. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Giving supraphysiological levels of testosterone and carboplatin or etoposide together may be an effective treatment for metastatic castration-resistant prostate cancer.
NCT06039371 ↗	Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study	Recruiting	University of Washington	Phase 2	2024-06-06	This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer). In patients that have developed progressive cancer in spite of standard hormonal treatment, administering supraphysiological testosterone may result in regression of tumors by causing deoxyribonucleic acid (DNA) damage in tumor cells that have adapted to low testosterone conditions. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Giving supraphysiological levels of testosterone and carboplatin or etoposide together may be an effective treatment for metastatic castration-resistant prostate cancer.

Clinical Trial Conditions for VIRILON

Condition Name

Condition Name for VIRILON
Intervention	Trials
Castration-Resistant Prostate Carcinoma	1
Hypogonadism	1
Malignant Urinary System Neoplasm	1
Metastatic Prostate Adenocarcinoma	1

Condition MeSH

Condition MeSH for VIRILON
Intervention	Trials
Hypogonadism	1
Prostatic Neoplasms	1
Urologic Neoplasms	1
Urologic Diseases	1

Clinical Trial Locations for VIRILON

Trials by Country

Trials by Country for VIRILON
Location	Trials
United States	2

Trials by US State

Trials by US State for VIRILON
Location	Trials
Washington	1
Georgia	1

Clinical Trial Progress for VIRILON

Clinical Trial Phase

Clinical Trial Phase for VIRILON
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for VIRILON
Clinical Trial Phase	Trials
Recruiting	2

Clinical Trial Sponsors for VIRILON

Sponsor Name

Sponsor Name for VIRILON
Sponsor	Trials
Emory University	1
National Cancer Institute (NCI)	1
University of Washington	1

Sponsor Type

Sponsor Type for VIRILON
Sponsor	Trials
Other	2
NIH	1

Last updated: April 26, 2026

VIRILON Clinical Trials, Market Analysis, and Projection

What is VIRILON and what is the current clinical-trial status?

Insufficient information. No drug-specific identifiers (active ingredient, ATC/INN, sponsor, formulation, or jurisdictional trial registry links) are provided for “VIRILON,” and no authoritative public sources can be linked to that name with enough specificity to produce a complete and accurate clinical-trials update and market projection.

---

What are the key clinical-trial programs and timelines to track?

Insufficient information. A clinical-trials update requires trial-level facts (phase, NCT/CTIS/EudraCT identifiers, enrollment status, primary endpoints, top-line data dates, and enrollment completion estimates). Those cannot be derived from “VIRILON” alone without risking materially incorrect statements.

---

What is the addressable market and competitive landscape?

Insufficient information. Market analysis depends on the drug’s therapeutic indication(s), mechanism-of-action, route of administration, line of therapy, label scope, dosing frequency, pricing region, and competitor set. Those inputs are not available from “VIRILON” as given.

---

What is the revenue and adoption projection for VIRILON?

Insufficient information. A revenue projection requires at minimum:

• projected launch timing (phase-to-approval pathway and regulatory milestones),
• expected label (indication and patient segmentation),
• pricing assumptions by geography and payer type,
• uptake curve assumptions (share vs. comparators),
• persistence/response rates that determine treated patient counts.

None of these are defined for “VIRILON.”

---

Key Takeaways

• A complete and accurate clinical-trials update and market projection for “VIRILON” cannot be produced from the provided information.
• Drug- and program-specific identifiers are required to avoid incorrect trial mapping, competitor misclassification, and faulty financial modeling.

---

FAQs

1. What clinical-trial sources are typically used for a VIRILON update?
   Trial registries such as ClinicalTrials.gov and EU registries, plus sponsor press releases and peer-reviewed publications.

2. What market inputs drive revenue projections for new drugs?
   Indication epidemiology, label scope, pricing, payer coverage, treatment duration, and competitive displacement.

3. How are timelines projected when Phase 2 data are incomplete?
   Via phase-readthrough assumptions based on historical approval rates and time-to-readout metrics for comparable programs.

4. What competitive factors matter most in adoption?
   Efficacy vs. standard of care, safety profile, convenience (route, dosing), and formulary access.

5. What makes one “drug name” hard to analyze without identifiers?
   Trade names are reused across regions and can map to different active ingredients, formulations, or indications.

---

References

[1] ClinicalTrials.gov. (n.d.). Database search results for VIRILON (requires specific identifiers to map correctly). https://clinicaltrials.gov
[2] European Union Clinical Trials Register. (n.d.). Database search results (requires specific identifiers to map correctly). https://www.clinicaltrialsregister.eu